Castle Biosciences, Inc.
NASDAQ:CSTLMedical - Diagnostics & Research
+$0.04 today
- Market cap
- $1.03B
- Beta
- 1.02
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.43
Volume 0.38M
Average 0.37M
CSTL Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Castle Biosciences, Inc.NASDAQ: CSTL
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$27.04M, compared with -$63.85M a year earlier.
Context
- Net debt amounted to 4.9% of total assets at the end of Q1 FY2026, down 7.8 pp from a year earlier.
- Net debt grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +57.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (79.82M) USD
- Year-over-year change
- +14.5%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (79.82M) | +14.5% |
| FY2024 | 2024-12-31 | (93.37M) | -11.8% |
| FY2023 | 2023-12-31 | (83.51M) | +23.8% |
| FY2022 | 2022-12-31 | (109.55M) | +65.9% |
| FY2021 | 2021-12-31 | (321.43M) | — |
Net Debt vs competitors
How CSTL compares with its peers on the latest reported figures
- CSTL's Mar 2026 net debt of -$27.04M is the 6th highest of the 8 companies compared; the peer median is $86.64M.
- Its year-over-year change of +57.6% is the 2nd highest of 8, against a peer median of +3.0%.
- Net debt amounts to 4.9% of total assets for CSTL, versus a peer median of 22.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $664.59M | -11.0% | +2.8% | 35.2% | |
| Jun 2026 | $302.83M | +17.8% | -3.5% | 22.4% | |
| Mar 2026 | $87.1M | +32.4% | -11.9% | 12.9% | |
| Jun 2026 | $86.64M | +69.2% | +39.6% | 65.6% | |
| Mar 2026 | $46.04M | +3.0% | — | 48.6% | |
| Mar 2026 | -$27.04M | +57.6% | — | 4.9% | |
| Mar 2026 | -$34.81M | -31.0% | — | 10.7% | |
| Jun 2026 | -$259.41M | -53.6% | — | 17.5% | |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding CSTL) | $86.64M | +3.0% | -0.4% | 22.4% | |
Competitors are the stored peer set for CSTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 329.63M | 122.95M | 98.84M | 119.71M | 116.73M |
| Short-term Investments | 0 | 135.68M | 144.26M | 173.42M | 182.78M |
| Net Receivables | 17.28M | 23.48M | 38.3M | 51.22M | 43.38M |
| Inventory | 2.02M | 3.98M | 7.94M | 8.14M | 10.25M |
| Other Current Assets | 4.81M | 6.21M | 6.29M | 7.67M | 7.96M |
| Total Current Assets | 353.74M | 292.29M | 295.64M | 360.15M | 361.1M |
| Property, Plant & Equipment (Net) | 16.88M | 26.5M | 37.74M | 62.71M | 112.24M |
| Goodwill | 0 | 10.69M | 10.69M | 10.69M | 10.69M |
| Intangible Assets | 88.92M | 115.66M | 106.64M | 95.54M | 88.88M |
| Long-term Investments | 1.31M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.72M | 2.2M | 2.63M | 2.15M | 5.65M |
| Total Non-current Assets | 108.83M | 155.04M | 157.71M | 171.08M | 217.46M |
| Total Assets | 462.57M | 447.33M | 453.34M | 531.24M | 578.56M |
| Account Payables | 2.55M | 4.73M | 10.27M | 6.9M | 18.71M |
| Short-term Debt | 0 | 0 | 0 | 278K | 417K |
| Tax Payables | 695K | 37K | 0 | 1.08M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 16.91M | 25.67M | 30.69M | 774K | 42.34M |
| Total Current Liabilities | 24.89M | 36.13M | 47.67M | 49.39M | 68.68M |
| Long-term Debt | 0 | 0 | 0 | 9.75M | 9.64M |
| Deferred Tax Liabilities | 635K | 428K | 206K | 1.61M | 2.34M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 18.29M | 0 | 0 | 0 | 1.5M |
| Total Non-current Liabilities | 25.95M | 12.05M | 14.4M | 26.01M | 39.01M |
| Total Liabilities | 50.83M | 48.18M | 62.07M | 75.4M | 107.68M |
| Common Stock | 25K | 27K | 27K | 28K | 30K |
| Retained Earnings | (93.77M) | (160.91M) | (218.37M) | (200.13M) | (224.28M) |
| Accumulated OCI | 0 | (381K) | 136K | 230K | 267K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 411.74M | 399.15M | 391.27M | 455.84M | 470.87M |
| Total Debt | 8.2M | 13.4M | 15.34M | 26.34M | 36.91M |
| Net Debt | (321.43M) | (109.55M) | (83.51M) | (93.37M) | (79.82M) |
Castle Biosciences, Inc.
NASDAQ:CSTL
Intrinsic Alpha fair value
Locked
Current Price
$33.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.